过去十年来 ,树突状细胞在刺激特异性免疫应答中关键作用的认定 ,使其应用到癌症和HIV的治疗领域中来。已有许多成功的报道 ,但这些应答的最佳途径和持续时间仍然有待进一步确定。DCs的质量、将肿瘤抗原转入DCs中的方法和免疫反应检测等有关的一些问题使得不同实验室中的实验结果很难进行比较。要确定基于DCs的肿瘤疫苗的作用、将DCs接种到病人体内的最有效途径和用来转入DCs中的肿瘤抗原等都需要作大量的工作 Over the past decade, the identification of the critical role of dendritic cells in stimulating specific immune responses has made them useful in the treatment of cancer and HIV. There have been many successful reports, but the best route and duration of these responses are still to be determined. The problems associated with the quality of DCs, methods for transferring tumor antigens into DCs, and immune response tests make it difficult to compare experimental results in different laboratories. To determine the role of DCs-based cancer vaccines, the most effective way to inoculate DCs into patients, and tumor antigens for transfer into DCs, a lot of work is needed